Redirecting to https://www.manilatimes.net/2025/10/11/tmt-newswire/pr-newswire/third-indication-for-kelun-biotechs-trop2-adc-sac-tmt-approved-for-marketing-by-nmpa-in-egfrm-nsclc-following-progression-on-egfr-tki-therapy/2198940